echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur J Epidemiol: Esophageal lesions strongly associated with increased risk of esophageal cancer

    Eur J Epidemiol: Esophageal lesions strongly associated with increased risk of esophageal cancer

    • Last Update: 2022-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Gastroesophageal cancer, including esophageal adenocarcinoma (EAC), esophageal squamous cell carcinoma (ESCC), cardiac adenocarcinoma (GCA), and gastric non-cardiac adenocarcinoma (GNCA), is one of the deadliest cancers in the world
    .


    Barrett's esophagus is the only known precancerous lesion of EAC and GCA


    Barrett's esophagus is the only known precancerous lesion of EAC and GCA

    The aim of this study was to assess the risk of gastroesophageal cancer in patients with various histopathological abnormalities of the esophagus, including Barrett's esophagus
    .

    The aim of this study was to assess the risk of gastroesophageal cancer in patients with various histopathological abnormalities of the esophagus, including Barrett's esophagus
    .


    The researchers correlated histopathological data from esophageal biopsies obtained between 1979-2014 with several national population-based registries in Sweden
    .


    Patients were followed from 2 years after the date of the first biopsy until cancer, death, removal, esophagectomy/gastrectomy, or the end of follow-up (as of December 31, 2016)


    During 831,394 person-years of follow-up, 367 cases of esophageal adenocarcinoma (EAC) were diagnosed
    .


    The incidence (IR) of EAC in individuals with normal morphology, inflammatory changes, and metaplastic changes on esophageal biopsy was 0.


    The incidence (IR) of EAC in individuals with normal morphology, inflammatory changes, and metaplastic changes on esophageal biopsy was 0.


    Cumulative incidence of esophageal cancer in different esophageal lesions

    Cumulative incidence of esophageal cancer in different esophageal lesions

    The incidence of EAC in patients with atypical hyperplasia intestinal metaplasia was 1.
    0/1000 person-years (95% CI 0.
    7-1.
    3), and the incidence rate of EAC in patients with non-dysplastic gastric/glandular metaplasia was 0.
    9/1000 person-years Years (95%CI 0.
    8-1.
    1), the incidence of EAC in patients with low-grade dysplastic columnar metaplasia was 2.
    9/1000 person-years (95%CI 2.
    0-4.
    2) ; the corresponding standardized incidence rates were 11.
    7 ( 95%CI 8.
    6-15.
    5), 12.
    0 (10.
    0-14.
    2) and 30.
    2 (20.
    5-42.
    8)
    .


    There was a moderate increase in the standardized incidence of cardia adenocarcinoma (GCA)


    The incidence of EAC in patients with atypical hyperplasia intestinal metaplasia was 1.


    Patients with esophageal inflammation and other metaplastic abnormalities other than Barrett's esophagus also had a higher risk of EAC and GCA compared with the general population


    Original source:

    Original source:

    Ekheden, I.


    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.